Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens

Mary Lou Clements; Emil Miskovsky; Morton Davidson; Thomas Cupps; Newton Kumwenda; Laurie A. Sandman; David West; Theresa Hesley; Virginia Ioll; William Miller; Gary Calandra; Saul Krugman

doi:10.1093/infdis/170.3.510

Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens

Mary Lou Clements, Emil Miskovsky, Morton Davidson, Thomas Cupps, Newton Kumwenda, Laurie A. Sandman, David West, Theresa Hesley, Virginia Ioll, William Miller, Gary Calandra, Saul Krugman

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

A single-blind, multicenter, phase II trial of yeast recombinant hepatitis B virus (HBV) vaccines containing surface antigen (S) alone or with PreS2 (PreS2+S) was conducted in 282 healthy HBV-seronegative adults aged 20-59 years. Each volunteer was randomly assigned to receive HBV vaccine containing 10 μg of S or one of three doses of PreS2 plus S: 2 + 10 μg, 4 + 20 μg, or 8 + 40 μg. The level of antibody to HBV surface antigen reached depended on the dose of S, not PreS2, received. In each vaccine group, volunteers 20-39 years old had higher titers of anti-PreS2 and antibody to S than those 40-59 years old. The age-related effect on immune response to HBV vaccination suggests that adults should beimmunized against hepatitis Bat as early an age as possible and that older persons may need a higher dose or booster immunizations to achieve durable immunity.

Original language	English (US)
Pages (from-to)	510-516
Number of pages	7
Journal	Journal of Infectious Diseases
Volume	170
Issue number	3
DOIs	https://doi.org/10.1093/infdis/170.3.510
State	Published - Sep 1994

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/170.3.510

Cite this

Clements, M. L., Miskovsky, E., Davidson, M., Cupps, T., Kumwenda, N., Sandman, L. A., West, D., Hesley, T., Ioll, V., Miller, W., Calandra, G., & Krugman, S. (1994). Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens. Journal of Infectious Diseases, 170(3), 510-516. https://doi.org/10.1093/infdis/170.3.510

Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens. / Clements, Mary Lou; Miskovsky, Emil; Davidson, Morton; Cupps, Thomas; Kumwenda, Newton; Sandman, Laurie A.; West, David; Hesley, Theresa; Ioll, Virginia; Miller, William; Calandra, Gary; Krugman, Saul.

In: Journal of Infectious Diseases, Vol. 170, No. 3, 09.1994, p. 510-516.

Research output: Contribution to journal › Article › peer-review

Clements, ML, Miskovsky, E, Davidson, M, Cupps, T, Kumwenda, N, Sandman, LA, West, D, Hesley, T, Ioll, V, Miller, W, Calandra, G & Krugman, S 1994, 'Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens', Journal of Infectious Diseases, vol. 170, no. 3, pp. 510-516. https://doi.org/10.1093/infdis/170.3.510

Clements, Mary Lou ; Miskovsky, Emil ; Davidson, Morton ; Cupps, Thomas ; Kumwenda, Newton ; Sandman, Laurie A. ; West, David ; Hesley, Theresa ; Ioll, Virginia ; Miller, William ; Calandra, Gary ; Krugman, Saul. / Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens. In: Journal of Infectious Diseases. 1994 ; Vol. 170, No. 3. pp. 510-516.

@article{2997b6f005e64bd0828f14087b827b7f,

title = "Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens",

abstract = "A single-blind, multicenter, phase II trial of yeast recombinant hepatitis B virus (HBV) vaccines containing surface antigen (S) alone or with PreS2 (PreS2+S) was conducted in 282 healthy HBV-seronegative adults aged 20-59 years. Each volunteer was randomly assigned to receive HBV vaccine containing 10 μg of S or one of three doses of PreS2 plus S: 2 + 10 μg, 4 + 20 μg, or 8 + 40 μg. The level of antibody to HBV surface antigen reached depended on the dose of S, not PreS2, received. In each vaccine group, volunteers 20-39 years old had higher titers of anti-PreS2 and antibody to S than those 40-59 years old. The age-related effect on immune response to HBV vaccination suggests that adults should beimmunized against hepatitis Bat as early an age as possible and that older persons may need a higher dose or booster immunizations to achieve durable immunity.",

author = "Clements, {Mary Lou} and Emil Miskovsky and Morton Davidson and Thomas Cupps and Newton Kumwenda and Sandman, {Laurie A.} and David West and Theresa Hesley and Virginia Ioll and William Miller and Gary Calandra and Saul Krugman",

note = "Funding Information: Received 12 January 1994; revised 13 April 1994. The study protocol adhered to guidelines of the US Department ofHealth and Human Services and was approved by the institutional review boards at Johns Hopkins University Medical Institutions. Georgetown University Hospital. and University Hospital of New York University Medical Center. Signed informed consent was obtained from all volunteers. Some authors are stockholders in Merck (D.W.•T.H .• V.I.. W.M.. a.c.). Financial support: Merck Research Laboratories and Fogarty Center. National Institutes of Health. Reprints or correspondence: Dr. Mary Lou Clements. Johns Hopkins University. Center for Immunization Research. 624 N. Broadway. Hampton House 225. Baltimore. MD 21205.",

year = "1994",

month = sep,

doi = "10.1093/infdis/170.3.510",

language = "English (US)",

volume = "170",

pages = "510--516",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens

AU - Clements, Mary Lou

AU - Miskovsky, Emil

AU - Davidson, Morton

AU - Cupps, Thomas

AU - Kumwenda, Newton

AU - Sandman, Laurie A.

AU - West, David

AU - Hesley, Theresa

AU - Ioll, Virginia

AU - Miller, William

AU - Calandra, Gary

AU - Krugman, Saul

N1 - Funding Information: Received 12 January 1994; revised 13 April 1994. The study protocol adhered to guidelines of the US Department ofHealth and Human Services and was approved by the institutional review boards at Johns Hopkins University Medical Institutions. Georgetown University Hospital. and University Hospital of New York University Medical Center. Signed informed consent was obtained from all volunteers. Some authors are stockholders in Merck (D.W.•T.H .• V.I.. W.M.. a.c.). Financial support: Merck Research Laboratories and Fogarty Center. National Institutes of Health. Reprints or correspondence: Dr. Mary Lou Clements. Johns Hopkins University. Center for Immunization Research. 624 N. Broadway. Hampton House 225. Baltimore. MD 21205.

PY - 1994/9

Y1 - 1994/9

N2 - A single-blind, multicenter, phase II trial of yeast recombinant hepatitis B virus (HBV) vaccines containing surface antigen (S) alone or with PreS2 (PreS2+S) was conducted in 282 healthy HBV-seronegative adults aged 20-59 years. Each volunteer was randomly assigned to receive HBV vaccine containing 10 μg of S or one of three doses of PreS2 plus S: 2 + 10 μg, 4 + 20 μg, or 8 + 40 μg. The level of antibody to HBV surface antigen reached depended on the dose of S, not PreS2, received. In each vaccine group, volunteers 20-39 years old had higher titers of anti-PreS2 and antibody to S than those 40-59 years old. The age-related effect on immune response to HBV vaccination suggests that adults should beimmunized against hepatitis Bat as early an age as possible and that older persons may need a higher dose or booster immunizations to achieve durable immunity.

AB - A single-blind, multicenter, phase II trial of yeast recombinant hepatitis B virus (HBV) vaccines containing surface antigen (S) alone or with PreS2 (PreS2+S) was conducted in 282 healthy HBV-seronegative adults aged 20-59 years. Each volunteer was randomly assigned to receive HBV vaccine containing 10 μg of S or one of three doses of PreS2 plus S: 2 + 10 μg, 4 + 20 μg, or 8 + 40 μg. The level of antibody to HBV surface antigen reached depended on the dose of S, not PreS2, received. In each vaccine group, volunteers 20-39 years old had higher titers of anti-PreS2 and antibody to S than those 40-59 years old. The age-related effect on immune response to HBV vaccination suggests that adults should beimmunized against hepatitis Bat as early an age as possible and that older persons may need a higher dose or booster immunizations to achieve durable immunity.

UR - http://www.scopus.com/inward/record.url?scp=0027964485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027964485&partnerID=8YFLogxK

U2 - 10.1093/infdis/170.3.510

DO - 10.1093/infdis/170.3.510

M3 - Article

C2 - 8077707

AN - SCOPUS:0027964485

VL - 170

SP - 510

EP - 516

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -

Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this